Ferric pyrophosphate citrate - Rockwell Medical Technologies

Drug Profile

Ferric pyrophosphate citrate - Rockwell Medical Technologies

Alternative Names: FePPi dialysate - Rockwell Medical Technologies; FPC - Rockwell Medical Technologies; Iron supplemented dialysate - Rockwell Medical Technologies; SFP - Rockwell Medical Technologies; Triferic; Triferic® Iron Delivery Therapy; Triferic® IV Solution; Triferic® Intravenous Solution; Triferic® PD Solution; Triferic® Peritoneal Dialysis Solution; Triferic® Total Parenteral Nutrition Solution; Triferic® TPN Solution

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ash Access Technology; Charak LLC
  • Developer Rockwell Medical Technologies
  • Class Antianaemics; Diphosphates; Heavy metals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia

Most Recent Events

  • 12 Dec 2017 Rockwell Medical Technologies and Quimica Europea enters a license and supply agreement for ferric pyrophosphate citrate in Peru for Renal failure
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Iron deficiency anaemia in USA (Intraperitoneal, Infusion)
  • 30 Oct 2017 Rockwell plans a clinical trial (In children) in mid-2018 as the second part of the post-marketing commitment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top